What s new in IBD? Dr AB Hawthorne Consultant Gastroenterologist University Hospital of Wales Cardiff

Similar documents
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

Diarrhoea for the Acute Physician

NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL

Inflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital

Mucosal healing: does it really matter?

Implementation of disease and safety predictors during disease management in UC

Crohn's Disease. The What, When, and Why of Treatment

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Efficacy and Safety of Treatment for Pediatric IBD

A Case of Inflammatory Bowel Disease

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

Recent Advances in the Management of Refractory IBD

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital

Protocol for the management of acute severe ulcerative colitis in children

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

Positioning Biologics in Ulcerative Colitis

Medical Therapy for Pediatric IBD: Efficacy and Safety

The London Gastroenterology Partnership CROHN S DISEASE

Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων

Diarrhoea on the AMU. Dr Chris Roseveare

I B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES

INFLAMMATORY BOWEL DISEASE

Efficacy and Safety of Treatment for Pediatric IBD

Outline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

Crohn s Disease. Resident Lecture 1/17/19

Improving outcome of Inflammatory Bowel Disease in children

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

National Institute for Health and Care Excellence

Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

SURGERY FOR COLITIS THE BOTTOM LINE

Top 10 Things you need to know about IBD. Suresh Pola, MD Kaiser San Diego

Trust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)

Personalized Medicine in IBD

The Best of IBD at UEGW (Crohn s)

September 12, 2015 Millie D. Long MD, MPH, FACG

What is Crohn's disease?

Surgical Management of IBD. Val Jefford Grand Rounds October 14, 2003

To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,

Update on IBD. Dr Richard POLLOK Consultant Gastroenterologist and Honorary Senior Lecturer. Queen Mary s Hospital. St George s Hospital

JUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Common Questions in Crohn s Disease Therapy. Case

Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball

2nd Nottingham IBD Masterclass, 2017

Case Discussion. Nutrition in IBD. Rémy Meier MD. Ulcerative colitis. Crohn s disease

We will review the need for continuing treatment with you after 3 months and again after one year.

Identifying and Managing Patients with IBD at Risk for Progressive Disease

Doncaster & Bassetlaw Medicines Formulary

Current management options and recent advances in IBD

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC

Guideline Ulcerative colitis: management

Adverse Events From Biologic Agents in IBD

Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152

Which is the Safest Strategy to Treat Moderate to Severe IBD?

Personalized Medicine in IBD: Where Are We in 2013

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care

Algorithm for managing severe ulcerative colitis

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

GUIDANCE ON THE INDICATIONS FOR DIAGNOSTIC UPPER GI ENDOSCOPY, FLEXIBLE SIGMOIDOSCOPY AND COLONOSCOPY

Crohn's Disease. The What, When, and Why of Treatment

IBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital

Crohn's Disease. The What, When, and Why of Treatment

Pediatric Inflammatory Bowel Diseases

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor

CROHN S DISEASE FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS

John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah

Indications for use of Infliximab

Therapies for IBD: the Pipeline. New Therapeutic Agents in IBD

Join the conversation at #GIFORUMCCFA

Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Soura

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Update on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC

Michael D. Kreines, M.D.

Slide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology

Ali Keshavarzian MD Rush University Medical Center

Understanding Inflammatory Bowel Diseases (IBD):

IBD in teenagers Biological and Transition

Nutrition as primary therapy in IBD. Dr Clare Donnellan Leeds General Infirmary

Medical therapies and IBD

Efficacy of Vedolizumab as Induction Therapy for Inflammatory Bowell Disease in a «real-life» Study. Clinical Study

Dr David Rowbotham. The Leeds Teaching Hospitals NHS Trust NHS

OUNCE OF PREVENTION WORTH A POUND OF CURE

Management of the Hospitalized IBD Patient. Drew DuPont MD

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease

Transcription:

What s new in IBD? Dr AB Hawthorne Consultant Gastroenterologist University Hospital of Wales Cardiff

Case: Kelly age 19 Admitted via medical intake to local hospital with D&V for 10 days. Ate take-away pizza just before symptoms started. Friend also unwell. BO x5/day bloody diarrhoea. Griping abdominal pain. No travel. No FH IBD. Non-smoker Examination: P 130 reg. BP 138/85. T 37.8. Tender lower abdo. AXR:- Stool culture x2 sent Stool chart Hb 114 g/l Platelets 585 x10 9 /l WBC 16.4 x 10 9 /l CRP 67 mg/l, Albumin 31 g/l

Q.1 What is the most likely diagnosis? 1. Ulcerative Colitis 2. Salmonella gastroenteritis 3. Campylobacter gastroenteritis 4. Irritable bowel syndrome

Q.2 What treatment would you start initially? 1. Antibiotics 2. iv hydrocortisone 3. oral prednisolone 4. Antibiotics and steroids 5. Neither

Case: Kelly age 19 Admitted via medical intake to local hospital with D&V for 10 days. Ate take-away pizza just before symptoms started. Friend also unwell. BO x5/day bloody diarrhoea. Griping abdominal pain. No travel. No FH IBD. Non-smoker Examination: P 130 reg. BP 138/85. T 37.8. Tender lower abdo. AXR:- Stool culture x2 sent Stool chart Hb 114 g/l Platelets 585 x10 9 /l WBC 16.4 x 10 9 /l CRP 67 mg/l, Albumin 31 g/l

Acute severe UC: management In suspected acute UC start iv hydrocortisone 100mg qds Stool cultures and AXR Clexane Avoid opiates/anticholinergics Correct K + Failure to settle after 3-5 days iv steroids colorectal consultation and consider salvage therapy (infliximab or ciclosporin) After 3 days iv steroids:- Stool frequency x3-8, and CRP>45 or Stool frequency >8 gives 85% chance of colectomy (Travis criteria)

Kelly: Acute severe UC Day 5 (after weekend) No growth on stool cultures Still being sick Diarrhoea cont, still bloody x7 Albumin 14, CRP 161 Flexible sigmoidoscopy:- Would you consider medical salvage therapy?

Time to Colectomy Kaplan-Meier plot of time (days) from randomisation to colectomy, censored at 28/02/2014 Williams et al. UEGW 2014 OP084 Slide courtesy of Prof JG Williams

Acute severe UC: salvage therapy No difference between infliximab and ciclosporin in short and long-term outcomes: 70-80% discharged without colectomy: Ciclosporin switch to oral 5-6mg/kg/day for 3 months with azathioprine (check TPMT) Infliximab induction doses at 0,2,6 weeks. Combo therapy with azathioprine (SUCCESS trial). Maintenance? 50% colectomy at 2 years CysIF trial Laharie, D. et al. Lancet 2012;380:1909 CONSTRUCT Williams JG et al. Lancet Gastroenterol Hepatol 2016Online June 22, 2016 http://dx.doi.org/10.1016/s2468-1253(16)30003-6

Q.3 Acute UC in a 49 yr old man. Settling with iv ciclosporin, still on steroids. Sudden onset of central chest pain, worse on swallowing. Likely cause? 1. Reflux oesophagitis 2. Angina triggered by low Mg 3. Candida oesophagitis 4. Herpes simplex/cmv oesophagitis

Complications of therapy 39 yr old man recent in-pt with acute UC: On azathioprine 150mg od (3 weeks) + reducing prednisolone (5mg) + awaiting 3 rd dose infliximab Admitted with 24 hrs severe central abdominal pain with vomiting. Diagnosis? Pancreatitis Amylase 620 4% on azathioprine (within 4 weeks) Resolves on drug cessation More common on concomitant steroids More common with Crohn s HLA-DQA1-HLA-DRB1 variants Heterozygous 9% risk Homozygous 17% risk Heap et al Nature Genetics 2014

Complications of therapy? 32 yr old woman recovering from acute UC admission 8 weeks earlier On azathioprine 150mg od and mesalazine (Salofalk) Doctor: the azathioprine is making my hair fall out!

Complications of therapy? Doctor: the azathioprine is making my hair fall out! Telogen Effluvium: - 6-8 wks after acute illness - Scalp normal - Full recovery - NOT due to drugs - Exclude iron/zinc deficiency

Medical Therapy for UC 1 st line therapy: mesalazine 2 nd line therapy: azathioprine Biologics: - Anti-TNF therapy: infliximab (biosimilars), adalimumab, golimumab Vedolizumab gut-specific lymphocyte traffic inhibitor. Iv. Slow onset effect. Good safety data. NICE approved Tofacitinib (Pfizer) oral JAK 1,2,3 inhibitor. FDA approval for RA. JAK only expressed on immune cells

Implications of new medical therapies in UC Colectomy rates are falling (preceded biologics era) Colorectal cancer incidence lower Long-term corticosteroid use less Need for infection screening and vaccinations Cost

International genotype phenotype study in >34,000 patients Genotype determines disease location (mainly fixed over time) Ulcerative Colitis, Colonic Crohn s and Ileal Crohn s genetically distinct Little genetic association with disease behaviour (changes over time++) Disease behaviour in Crohn s Inflammatory Obstructive Penetrating Cleynen et al Lancet 2015;387:156

Crohn s disease Diarrhoea, abdominal pain and weight loss, with mouth ulcers

Atypical presentations of Crohn s disease Anorexia in a 16 yr old girl: Clinical: poor appetite due to nausea/pain on eating, cheilitis Tests: albumin, platelet count, B12 and folate Diagnosis: faecal calprotectin, MR enterogram, Irritable bowel syndrome : Clinical: FH? Tests: Hb, albumin, CRP? Diagnosis: Faecal calprotectin Colonoscopy if >150 Inflammatory low back pain Altered bowel habit and pain not due to NSAIDs?

Oral Crohn s disease More common in children/young adults Aphthous ulcers Angular cheilitis Glossitis Candida True oral Crohn s = OFG Non-specific

8 yr old boy is it Crohn s? Diarrhoea, abdominal pain, and growth failure Colonoscopy whole colon oedematous with cobble-stone appearance and granulomatous inflammation suggestive of Crohn s disease Treated with steroids and azathioprine good response Admitted with pneumonia on 2 occasions. CT scan suggests bronchiectatic changes. Diagnosis?? Chronic granulomatous disease - Neutrophil oxidation defects bacterial and fungal infection - More in boys (often X-linked defects) but milder AR defects - Diagnosis: Neutrophil oxidative function tests

Monogenic very early onset IBD Uhlig et al Gastroenterol 2014

Medical treatment of Crohn s disease Corticosteroids (budesonide for mild/moderate ileocaecal disease) Little role for mesalazine in small bowel Crohn s Dietary (exclusive enteral nutrition) Antibiotics Early use of azathioprine or methotrexate Biologics Anti-TNF therapy: infliximab (biosimilars), adalimumab Vedolizumab Ustekinumab (coming soon)

Ustekinumab (Stelara) Already available for psoriasis Higher doses for Crohn s: iv loading then sc 8 weekly ABT-74(Briakinumab) Ustekinumab Th-1 Th-17 ABT-74(Briakinumab) Ustekinumab

Complications of therapy Infection: bacterial, viral, fungal Surgical complications Haematological Lymphoma Non-melanoma skin cancer (SCC, BCC) Malignant melanoma

Complications of therapy Lupus-like syndrome (anti-tnf therapy) Arthralgia, +/- mucocutaneous and pleuropericardial inflammation 9% mild 1% severe requiring cessation. Correlates with dsdna titre Psoriaform rashes (anti-tnf therapy) 5% (1/3 required cessation) Palmoplantar pustulosis

What causes IBD? Khor et al Nature 2011

Answers to questions Q.1 1. ulcerative colitis Q2 Q3 Q4 2. iv hydrocortisone 4. Herpes simplex/cmv oesophagitis 4. Melkersson-Rosenthal syndrome